We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)698.55+26.51 (+3.94%)as of 4 Nov 2026
Funds that hold it1One fund per scheme
Held through a master fund10 buy the stock themselves
Largest weight in a single fund4.51%Of that fund's NAV
Median weight4.51%Half the funds hold more than this
What does IDXX do
IDEXX LABORATORIES INC /DE
Makes diagnostic test kits and lab instruments for pets and livestock. Most revenue comes from veterinary clinics that buy test kits and ongoing services
Where the revenue comes from, and how much is left as profit (FY2025)
For every 100 dollars of sales: cost of sales 38 · operating expenses 30 · other income adds 0 · tax and other items 7 · leaving 25 as net profit
Which funds let you invest in IDXX
Sorted by weight held, largest first
Investors in Thailand can buy IDXX through 1 mutual funds open to retail investors. Most of them (1 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds IDXX.
Showing 1 of 1 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
IDXX share price
0.00%
Price change over the selected periodN/A
50-day average
200-day average
Thai funds holding IDXX
1 funds · Highest 4.51% · Median 4.51%
How the weights are spread
Number of funds by weight range
0
0
1
0
0
0
< 1%1–3%3–5%5–8%8–12%12%+
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
ONEAM
How Thai money reaches IDXX
1 master funds
Master fund
Thai funds using this route
Master fund's IDXX weight
iShares U.S. Medical Devices ETF
1
4.51%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Valuation and key ratios
IDEXX LABORATORIES INC /DE · NASDAQ · Fiscal year ends in January
Market cap55.2B USD0.08 billion shares
P/E53.4xPrice ÷ FY2025 EPS 13.08
Forward P/E40.7xBased on forecast 12-month earnings
P/S11.8x
EV/EBITDA33.3x
Dividend yield0.00%0.00 USD per share a year
ROE66.2%Net profit ÷ shareholders' equity
Debt to equity (D/E)0.28xInterest-bearing debt
Beta1.55Against the S&P 500
Gross margin61.8%FY2025
Operating margin31.6%FY2025
Net margin24.6%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth7.6%Steady growth
Yearly average over the last 4 years · Latest annual sales 4.3B USD
Profit from sales25%Highly profitable
For every 100 dollars of sales, about 25 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price−3.3%Down
Now 8.9% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 7.6% a year on average · EPS grows 11.1% a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY20213.2B USD745.0M USD
FY20223.4B USD679.0M USD
FY20233.7B USD845.0M USD
FY20243.9B USD888.0M USD
FY20254.3B USD1.1B USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY20251.1B USD294.0M USD
Q3 FY20251.1B USD275.0M USD
Q4 FY20251.1B USD248.0M USD
Q1 FY20261.1B USD278.0M USD
Q2 FY20261.2B USD338.0M USD
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
3.2B USD
3.4B USD
3.7B USD
3.9B USD
4.3B USD
Gross profit
1.9B USD
2.0B USD
2.2B USD
2.4B USD
2.7B USD
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 698.55 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.50 on a scale of −1 to +1 · 1254 bars
RSI(14)
79.4
ADX(14)
41.2
Position in the price range
100%
Weekly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 262 bars
RSI(14)
72.2
ADX(14)
22.2
Position in the price range
74%
Monthly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
62.1
ADX(14)
17.9
Position in the price range
83%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
599.09
614.47
Above
20 days
568.50
583.67
Above
50 days
541.78
558.34
Above
100 days
550.80
557.11
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
79.44
Down
MACD(12,26)
31.90
Up
ADX(14)
41.18
Neutral
ATR(14) % of price
2.35
Neutral
Support and resistance (weekly pivots)
s3518
s2535
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in IDXX, not the look-through weight · Past performance is not a guarantee of future performance
ONE-MEDTECHONE MEDICAL TECHNOLOGY FUND